Cargando…

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake. Objective: The aim of this study was to analyze multiple facets of biosimilar competition of TNF-alpha inhibitors in Europ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Car, Elif, Vulto, Arnold G., Houdenhoven, Mark Van, Huys, Isabelle, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160635/ https://www.ncbi.nlm.nih.gov/pubmed/37153785 http://dx.doi.org/10.3389/fphar.2023.1151764

Ejemplares similares

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
por: Barcina Lacosta, Teresa, et al.
Publicado: (2023)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021)

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
por: Luukkanen, Saana V., et al.
Publicado: (2022)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
por: Moorkens, Evelien, et al.
Publicado: (2017)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
por: Vandenplas, Yannick, et al.
Publicado: (2023)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
por: Barbier, Liese, et al.
Publicado: (2021)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
por: Barbier, Liese, et al.
Publicado: (2022)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Competitive pricing on online markets: a literature review
por: Gerpott, Torsten J., et al.
Publicado: (2022)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

Market Prices
por: Beecher, Thos. K.
Publicado: (1885)

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2019)

The impact of competition on quality and prices in the English care homes market
por: Forder, Julien, et al.
Publicado: (2014)

Market competition and price of disease management programmes: an observational study
por: van Dijk, Christel E, et al.
Publicado: (2014)

PHARMACEUTICAL PRICING IN EMERGING MARKETS: EFFECTS OF INCOME, COMPETITION, AND PROCUREMENT
por: Danzon, Patricia M, et al.
Publicado: (2015)

Dynamics of price competition in Italian pharmaceutical off-patent market
por: Perna, Serena, et al.
Publicado: (2022)

Market Integration and Price Dynamics under Market Shocks in European Union Internal and External Cheese Export Markets
por: Xue, Huidan, et al.
Publicado: (2022)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_24dfp7rcknnf46f3t4v2s17ku6